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                                             ABSTRACT 
COMPARISON OF THREE DIFFERENT DOSES OF 
DEXMEDITOMIDINE AS ADJUVANT TO BUPIVACAINE IN SUPRA 
CLAVICULAR BRACHIAL PLEXUS BLOCK FOR UPPER LIMB 
ORTHOPAEDIC SURGERIES 
Dr.B.Dhanalakshmi, Dr.Annie geetha, Dr.Pratheepa Durairaj, Dr.J.Edward 
jhonson, Dr.A.Vasuginathan. Kanyakumari government medical 
college,Nagercoil. 
Background and goals of study: The aim and objective of the study is  to 
compare the three different doses of dexmeditomidine and to know the optimal 
dose of  dexmeditomidine as adjuvant to bupivacaine in supra clavicular 
brachial plexus block for upper limb orthopedic surgeries. 
Methods : We studied 60 ASA  l & ll patients undergoing  upper limb 
orthopaedic surgeries including  fracture humerus and fracture radius and ulna 
under supra clavicular brachial plexus block done by paresthesia technique.   . 
Patients were randomly allocated to three groups. Group A :( n-20) – 30 ml 
0.33% bupivacaine + dexmeditomidine 50mcg.Group B :( n-20) – 30ml 0.33% 
bupivacaine + dexmeditomidine 75mcg.Group C: (n-20) – 30ml 0.33% 
bupivacaine + dexmeditomidine 100mcg. Patients were evaluated for sensory & 
motor block onset and duration, duration of analgesia, sedation score, 
complications, hemodynamic parameters including non-invasive blood pressure, 
pulse rate , saturation intra operatively and post operatively. 
Results & Conclusion : Sensory block onset was longer in group A (16.3±3.31) 
than group B(12.4±2.5) which is longer than group C (7.35±1) and motor block 
onset also longer in group A (20.4±2.7) than group B (16.15±2.89) which is 
longer than group C(12.15±2.81). The duration of both sensory and motor block 
was longest  with group C (sensory mean 722.5±55.1minutes, motor mean 
704±41.4minutes) compared with group B (sensory mean 625.5±72.7 minutes , 
motor mean 604±98.6 minutes) which is longer than group A (sensory mean 
432±69.8minutes, motor mean 426.5±81.8). The mean duration of analgesia 
was dose dependent (tableB5) with C (736±67.1) >B (642±76.5) > 
A(480.5±81.3)minutes.  We conclude that dexmeditomidine 100µg is an optimal 
dose to provide prolonged post-operative   analgesia without significant side 
effects 
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INTRODUCTION 
 
 In peripheral nervous system blockade, a local anesthetics injected into the 
tissues or in the proximity to peripheral nerves. Initially these techniques were 
empirical resulting in failure and complications. In the last 3-4 decades the new 
scientific knowledge about pain and new modalities for conducting peripheral 
nerve blockade helped to reduce failure rate and complications and also extended 
its applications. 
Peripheral nerve blocks can provide ideal operating conditions, post-
operative analgesia and diagnostic, therapeutic role in acute and chronic pain 
management. The basis for use of peripheral nerve blocks is to interrupt 
nociceptive impulses coursing in the peripheral nerves. 
The advantages of peripheral nerve blocks when compared to the general 
anesthesia are it causes less interference with physiology of human body, less 
stress response and avoids using of many drugs and its related complications. 
In 1880’s American Surgeon Halstead and Hall described the injection of cocaine 
into the peripheral sites. In 1885 James Leonard corning recommended use of 
esmarch bandage to prolong cocaine induced block .In 1903 Braun used 
epinephrine as a chemical tourniquet. 
12 
 
Local anesthetics developed in first half of 20
th
 century were amino ester 
compounds with unfavorable properties of short duration of action, systemic 
toxicity and allergic reactions. This lead to advent of long acting amino amide 
compounds. The drawbacks of which are delayed onset of action, varying quality 
of blockade and inadequate post-operative analgesia. 
Adjuvants are added to local anesthetics in peripheral nerve blocks to 
fasten the onset of action, to prolong the duration of action and improve the 
quality of blockade. 
Various adjuvants like morphine, fentanyl, sufentanil, clonidine, 
midazolam, ketamine, neostigmine are added to local anesthetics. Previously, 
clonidine the α2 agonist was used as adjuvant to local anaesthetic which was 
associated with adverse effects like hypotension and bradycardia. In our study 
dexmeditomidine, the other drug belongs to α2 agonist is used as an adjuvant to 
potentiate the action of local anaesthetics. Since dexmeditomidine has α2:α1 
selectivity ratio of 1620:1 as compared to 220:1 for clonidine, it decreases 
unwanted side effects of α1 and much more sedative and analgesic. 
This study is designed to compare the effect of three different doses of 
dexmeditomidine when added to bupivacaine in brachial plexus block. 
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AIM OF THE STUDY 
 
The aim and objective of the study is: 
To compare the three different doses of dexmeditomidine and to know the 
optimal dose of dexmeditomidine as adjuvant to bupivacaine in supra clavicular 
brachial plexus block for upper limb orthopedic surgeries. 
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ANATOMY OF THE BRACHIAL PLEXUS 
 
Brachial plexus block is one of the most commonly used peripheral nerve 
blocks in clinical practice. It can be used as the sole anaesthetic technique or in 
combination with general anaesthesia for intra operative and post-operative 
analgesia. Continuous catheterization of the brachial plexus is one of the best 
methods of post-operative analgesia. 
For successful brachial plexus blockade it is essential to know the anatomy 
of the brachial plexus in terms of vascular, muscular, fascial relationships of the 
nerves throughout its formation and distribution. 
In its course from the intervertebral foramina to the upper arm, the plexus 
composed of roots, trunks, cords, divisions and terminal branches which are 
formed by process for combining and dividing. 
 
FORMATION OF THE PLEXUS 
ROOTS 
 The brachial plexus arises from the union of the spinal nerve roots of C5, 
C6, C7, C8 and T1 and often it also contains few fibers from the C4 above and 
T2 below. Occasionally, the plexus is mainly derived from C4-C8 (Pre fixed 
plexus) or from C6-T2 (post fixed plexus). These variations are usually 
associated with the presence of anamolous first rib. 
15 
 
 
TRUNKS 
After they leave their intervertebral foramina, the roots of the plexus 
appear in the interscalene groove between the scalenus anterior and scalenus 
medius  muscles. There the roots combine to form trunks. The C5 and C6 roots 
combine to form the upper trunk, C7 continues as the middle trunk and C8 and 
T1 combines to form the lower trunk. 
After passing through the interscalene groove the plexus lies close 
together, move towards first rib. When crossing the first rib, the trunks of the 
plexus lies dorso lateral to the sub clavian artery and are enclosed along with the 
artery by a connective tissue sheath. 
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DIVISIONS 
 The plexus runs under the middle of the clavicle into the tip of the axilla. 
Behind the clavicle each trunk divides into anterior and posterior divisions. 
CORDS 
 In the upper part of the axilla the six divisions combine to form lateral, 
medial and posterior cords. 
 The lateral cord is formed by the union of anterior divisions of the upper 
and middle trunks. 
 The medial cord is the continuation of the anterior division of the lower 
trunk. 
 The posterior cord is formed by union of the posterior divisions of all the 
three trunks. 
Terminal branches – Lower down in the axilla the cords give rise to terminal 
branches. 
In summary, there are 
1. Five roots – The anterior primary rami of C5-C8 and T1. 
2. Three trunks (in the posterior triangle) 
a. Upper trunk – C5 & C6 
b. Middle trunk – C7 
c. Lower trunk – C7 & T1 
3. Six divisions (behind the clavicle) 
Each trunk divides into an anterior and posterior division. 
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4. Three cords (within the axilla) 
a. Lateral cord – anterior divisions of upper and middle trunks C5-C7 
b. Medial cord – anterior division of lower trunk C8-T1 
c. Posterior cord – posterior division of all three trunks C5-T1 
 
RELATIONSHIP OF THE BRACHIAL PLEXUS 
Roots 
 These lie between the scalenus anterior and medius muscles. It lies above 
the second part of subclavian artery. The classical interscalene approach to the 
brachial plexus blocks the plexus at the root level. 
Trunks 
 In the posterior triangle, the trunks of the plexus invested in a sheath of 
prevertebral fascia, are superficially placed, being covered only by skin, platysma 
and deep fascia. 
The upper and middle trunks lie above the subclavian artery, the lower 
trunk lie behind the artery. The subclavian perivascular approach of plexus blocks 
the trunks 
Divisions 
 At the lateral border of the first rib, the trunks bifurcate into divisions 
which are situated behind the clavicle, the subclavius muscle and the 
suprascapular vessels.  
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Cords 
 The cords are formed at the apex of the axilla and become grouped around 
the axillary artery, the medial cord lies behind the artery, the posterior and lateral 
cords lies lateral to the artery but behind the pectoralis minor muscle. The cords 
are arranged as signified by their names. 
Terminal branches 
 They are formed lower down in the axilla at the lateral border of pectoralis 
minor muscle. The axillary approach causes blockade at this level. 
 
Branches 
1. Branches of roots 
a. To longus cervicis (C5-8) 
b. To the scalenus muscles (C5-8) 
c. Nerve to rhomboids (C5) 
d. Nerve to serratus anterior (C5-7) 
e. Contribution to the phrenic nerve 
Roots receive sympathetic fibres from 
a. Grey rami from the cervical sympathetic chain 
b. C5 and C6 from the middle cervical ganglion 
c. C7 and C8 from the inferior cervical ganglion 
d. T1 from the ganglion of T1 
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 2. Branches of trunks 
a. Nerve to subclavius (C5,6) 
b. Suprascapular nerve (C5,6) 
     3. Branches of cords 
a. Lateral cord 
Lateral pectoral nerve (C5-7) 
Musculo cutaneous nerve (C5-7) 
Lateral head of median nerve (C6,7) 
b. Medial cord 
Medial pectoral nerve (C8, T1) 
Medial cutaneous nerve of arm (C8, T1) 
Medial cutaneous nerve of forearm (C8, T1) 
Medial head of median nerve (C8, T1) 
Ulnar nerve (C7-8, T1) 
c. Posterior cord 
Upper subscapular nerve (C5,6) 
Nerve to lattismusdorsi (C6-8) 
Lower subscapular nerve (C5,6) 
Axillary nerve (C5,6) 
Radial nerve (C5-8, T1) 
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ANATOMICAL CONSIDERATIONS 
The anatomic factors which determine the success and complications of the 
blockade are, 
- The perivascular sheath 
- The vertical arrangement of the cervical roots 
- The interconnection due to combining dividing recombining and 
redividing. 
- Relationship of site of needle entry to vital structures. 
 
IMPORTANCE OF PERIVASCULAR SHEATH 
 The perivascular sheath is a fibrous sheath covering the brachial plexus in 
its entirety. It extends from the origin of scalenus muscles down to middle of the 
upper arm. This sheath gives a classical “Pop Off” feel when pricked by the 
needle. 
This sheath is the single most important factor in determining the success 
of blockade. The plexus can be blocked by introducing the needle at any point 
along the sheath 
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TECHNIQUES OF BRACHIAL PLEXUS BLOCK 
History 
 The block was first performed by William Steward Halsted in 1889 using 
cocaine by directly exposing the plexus in the neck. Hirschel first described the 
percutaneous approach. Kulenkamf first described the classical supraclavicular 
approach. Winnie and Collins first described the subclavian perivascular block. 
The infraclavicular approach was first developed by Raj. The axillary approach 
was first performed by Accardo and Adriano in 1949. 
Techniques 
 According to the proposed site of surgery on the upper limb, brachial 
plexus can be blocked at various levels. The common sites of approach to the 
plexus are, 
a. Interscalene approach 
b. Supraclavicular approach 
i. Classical approach 
ii. Subclavian perivascular technique 
iii. Plumb bob technique 
c. Infraclavicular approach 
d. Axillary approach 
e. Posterior approach 
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SUPRACLAVICULAR BRACHIAL PLEXUS BLOCK 
a) Classical approach of Kulenkampff
6
 
The patient is positioned in supine position with head turned away from the 
side to be blocked. The arm is adducted and extended towards ipsilateral knee. 
The needle insertion site is 1cm posterior to the clavicular midpoint. A 22 gauge 
4cm needle is directed caudad and posterior direction until paraesthesia elicited 
or rib is hitched. After negative aspiration for blood calculated dose of local 
anaesthetic is injected. 
 
b) Subclavian perivascular technique of Winnie and Collins
6
 
 The interscalene groove is palpated and tracked down at its most inferior 
point subclavian artery pulse palpated. The needle is inserted just above and 
posterior to the pulse and directed caudally. Needle is advanced until paraesthesia 
elicited and the local anaesthetic injected after negative aspiration for blood 
 
c) Plumb-bob supra clavicular block
6
 
 The needle entry site is at the point where the lateral border of the 
sternocleido mastoid muscle inserts into the clavicle. The needle is inserted while 
mimicking a plumb bob suspended over the needle entry site until eliciting 
paraesthesia. 
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Complications 
 1 .Pneumothorax 
       This is the commonest complication after supra clavicular brachial plexus 
block with prevalence ranges from 0.5 to 6 %. It occurs due to apex of lung lies 
just medial and posterior to the brachial plexus. The symptoms may be sudden 
onset of chest pain and may associate with dyspnea and cough and it may take 24 
hour to manifest. On examination there may be increased resonance on 
percussion and decreased breath sounds on auscultation and may beconfirmed wit 
chest xray in upright position.This condition may be managed with inter costal 
chesttube insertion in 5
th
 inter costal space in  
 2. Horner’s syndrome 
      This consist ofmiosis, anhidrosis, ptosis due to concomitant stellate ganglion 
block 
 3. Phrenic nerve palsy  
     It is less likely than inter scalene brachial plexus block 
4. Intra vascular injection  
    Local anaesthetic may be accidentaly injected into intravascularly resulting in 
local anaesthetic toxicity. To avoid this the drug should be aspirated every 3-5 ml 
while injecting 
 5. Haematoma formation 
 6. Nerve injury 
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APPLIED PHYSIOLOGY 
 The nervous tissue is made up of neurons which are the basic building 
blocks. Nerves consist of a cell body, dendrites and an axon which ends as a 
presynaptic terminal
.1
. Nerves may be myelinated or unmyelinated. In myelinated 
nerve fibres (all large motor and sensory) myelin is made up of Schwann cells 
that wrap around the axon up to 100 times. Whereas in unmyelinated nerve, 
fibresare simply surrounded by Schwann cell without wrapping. 
Nerve fibres are classified as A, B and C according to their size&velocity 
of conduction. A and B fibres are myelinated whereas C fibres areunmyelinated
.1
 
The largest A fibres are subdivided into alpha, beta, gamma, delta. Aα fibres 
supply skeletal muscle; Aβ fibres transmit tactile sensation; Aγ fibres supply 
skeletal muscle spindle; Aδ fibres transmit acute pain; Type C fibres transmit 
dull, aching pain
.1
 
          Within the myelinatedfibres there are interruptions called nodes of Ranvier. 
Action potentials pass from node to node rather than continuously as in 
unmyelinated C fibres. Two or three adjacent nodes must be affected to prevent 
conduction. A typical peripheral nerve consists of several axon bundles and each 
axon has its own covering, the endoneurium. Each fascicle of many axons 
covered by perineurium and the entire nerve wrapped by epineurium. To reach 
nerve axon, a local anaesthetic molecule must traverse four to five layers of 
connective tissue or lipid membranous barrier. 
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PHYSIOLOGY OF NERVE CONDUCTION 
 Nerves allow conduction of electrical signals from central nervous system 
to periphery without loss of information. 
Nerve membrane is made up of a bimolecular framework of phospholipid & 
protein channels protruding through the lipid bilayer. The globular protein is a 
sodium or potassium ion channel. 
When the nerve is stimulated, following changes occurs in the cell 
membrane. 
 
Resting membrane potential 
At rest, an electrical potential of 70mV exist across the membrane with the 
negative potential inside of the cell relative to the outside of the cell. This is due 
to higher concentration of sodium ions outside than inside of the cell. 
Potassium channels maintain the resting membrane potential because more 
K
+
 channels opened at rest and permeability to K+ is greater than permeability to 
Na
+
. 
Depolarization Phase 
 During excitation, Na+ channels will open and allowing sodium ions flow 
into the cell thereby depolarising the membrame. 
Repolarization phase 
 Because of opening of voltage gated K
+
 channels, potassium ions pass out 
of the cell so that electrical neutrality is maintained 
26 
 
 
LOCAL ANAESTHETIC MODE OF ACTION 
  
Local anaesthetics reversibly inhibit peripheral nerve conduction by blocking 
voltage gated sodium and potassium channels on the internal cell membrane
7
 
Binding of local anaesthetics to the sodium channel prevents opening of 
the channel by inhibiting the conformational changes that underlie channel 
activation. 
As the concentration of local anaesthetics increases, the height of action 
potential is reduced, the firing threshold elevated, the spread of impulse 
conduction slowed, the refractory period lengthened. 
Peripheral nerves are differentially sensitive to local anaesthetics. Smaller 
the fibre diameter the greater its blockade. Myelinated fibres more sensitive than 
unmyelinated fibres. Aγ spindle efferents,  Aδ nociceptive fibres and B fibres are 
easily blocked while C fibres are less susceptible to block. 
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PHARMACOLOGY OF BUPIVACAINE 
 
 
 
Bupivacainehydrochloride is an amino-amide local anaesthetic synthesized 
by EKENSTAM et al in 1957 and first used by L.J. Telivuo in 1963. It is a 
member of the homologous series of n-alkyl substituted pipecholylxylidines. 
It is available for clinical use as racemic mixtures of the R&S enantiomers 
(50:50). The S enantiomer of bupivacaine is less toxic than commercially 
available racemic mixtures. 
 
Physicochemical Properties 
 Bupivacaine has butyl group on the piperidine nitrogen atom of the 
molecule. It is more lipid-soluble and highly protein bound. The physicochemical 
properties of bupivacaine are 
Molecule weight     - 288  
Protein binding     - 95% 
Partition coefficient    - 346 
28 
 
Pka       - 8.1 
Lipid solubility     - 28 
Relative conduction blocking potency  - 8 
 
Pharmacological properties 
 Bupivacaine is very stable to acids, alkalis and repeated autoclaving. 
Bupivacaine undergoes metabolism by aromatic hydroxylation, N-dealkylation, 
amide hydrolysis and conjugation. Alpha1 – acid glycoprotein is the most 
important plasma protein binding site for bupivacaine 
Bupivacaine is 3-4 times as potent as lignocaine; hence 0.5% solution is 
approximately equivalent to 2% lignocaine. It causes more sensory block than 
motor block. 
Duration of action is between 5 and 16 hours and it is one of the longest 
acting local anaesthetic which is related to binding to the nervous tissue. 
 
Pharmacokinetics 
 After injected into subarachnoid space and peripheral nervous site, it gets 
absorbed by the nerve roots and rapidly absorbed from the site of injection. The 
rate of absorption depends on the vascularity and presence of vasoconstrictors. 
Because of high lipid solubility, it easily penetrates nerve and vascular tissue. 
Small percentage of absorbed bupivacaine is excreted unchanged in urine and the 
remainder is metabolized in liver.  
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Volume of distribution  = 72 litres 
Elimination half life = 210 minutes 
Clearance = 0.47 litres / minute 
 
Pharmacodynamics 
Cardiovascular system
6
 
 Bupivacaine has dose related effect on the heart. In purkinje fibres and 
ventricular muscles it depresses the rapid phase of depolarization and in 
bupivacaine treated papillary muscles the rate of recovery from use dependent 
blockade is slower which results in incomplete restoration of sodium channel 
availability in between action potentials. This results in arrhythmogenic potential 
of bupivacaine. 
Respiratory System 
 Systemic absorption of bupivacaine stimulates the ventilator response to 
carbon dioxide
6
 
Gastro intestinal system 
            Bupivacaine when administered as continuous or intermittent epidural 
infusion associated with increased plasma concentrations of transaminases 
enzyme 
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Central Nervous System 
 The CNS is vulnerable to toxicity and mechanism of toxicity may be local 
an aesthetics induced increased intra cellular calcium ion concentration. The risk 
of transient neurologic symptoms less than lignocaine.  
 
DRUG DOSAGE 
 The maximal dose of bupivacaine is 2.5mg/kg and the strength used is 
0.125% - 0.75% with or without epinephrine. Epinephrine does not greatly 
prolong its effect but reduces its toxicity. 
 
Clinical uses 
 Spinal anaesthesia 
 Epidural anaesthesia 
 Caudal anaesthesia 
 Continuous epidural anaesthesia 
 Peripheral nerve block 
 Infiltration anaesthesia 
 
TOXICITY  
    Local an aesthetic systemic toxicity (LAST) are range from mild systemic 
symptoms to cardiovascular (hypertension, hypotension, tachycardia, bradycardia 
31 
 
, ventricular arrhythmia, cardiac arrest) and central nervous system symptoms( 
seizure , coma, respiratory depression) 
CVS Toxicity 
 Accidental IV Injection of bupivacaine may result in precipitous 
hypotension, cardiac dysrhythmia and atrioventricular heart block. After IV 
injection protein binding sites quickly saturated leaving significant free drug 
available for diffusion into conducting tissue of heart. Cardiotoxic plasma 
concentration of bupivacaine is 8-10mcg/ml. 
The R enantiomer of bupivacaine is more toxic than S enantiomer. 
CNS Toxicity 
 Early symptoms of CNS toxicity are circumoral numbness, tongue 
paraesthesia, dizziness followed by tinnitus, blurred vision, tonic clonicseizures, 
respiratory arrest often develops. 
Treatment 
Treatment of local anaesthetic systemic toxicity includes supportive treatment 
with application of supplemental oxygen and injection thiopentone sodium or 
propofol for seizure activity . Now the treatment is emphasised on 20% lipid 
emulsion. Lipid emulsion consist of soya bean oil made isotonic with glycerin.It 
will absorb the local anaesthetics into the lipid layers  
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PHARMACOLOGY OF DEXMEDETOMIDINE 
 
 Dexmedetomidine is a selective α2 adrenoreceptor agonist which received 
FDA approval in 1999. Dexmedetomidine has 1600:1 preference for α2 receptors 
relative to α1 receptors. It is used as adjunct to regional, local, general 
anaesthetics. 
Dexmedetomidine is an attractive choice in perioperative clinical setting 
because it has many favourable characteristics like analgesia, ‘rousable’ sedation, 
hemodynamic stability and anaesthetic sparing property. 
Physiology of α2 – adrenoceptors 
 α2-adrenoceptors are found in peripheral and central nervous system and 
also in liver, kidney, vascular smooth muscles, platelets.
1
 
There are three types of receptor. 
α2A – found in CNS which responsible for the sedative, analgesic, sympatholytic 
effect. 
α2B – found mainly in vasculature, which responsible for short term hypertensive 
responses. 
α2C – found in CNS, responsible for anxiolytic effects. 
 All these receptors produce cellular action by signaling through G-protein. 
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MECHANISM OF ACTION 
 α2adrenoceptors are found in many site of CNS with highest density found 
in locus ceruleus, which is the predominant noradrenergic nuclei of brain stem. 
Locus ceruleus is site of origin of descending medullospinal noradrenergic 
pathway which is modulator of nociceptive neurotransmission. 
Presynaptic activation of α2A adrenoceptor results in inhibition of 
norepinephrine release which results in sedative, hypnotic effects. Post synaptic 
activation of this receptor results in decreased sympathetic activity and leads to 
hypotension, bradycardia
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The analgesic mechanism of dexmedetomidine is due to stimulation of α2 
receptors at the substantia gelatinosa of spinal cord, inhibition of release of 
substance P, and preventing nor adrenaline release at the nerve endings
.6
 
Analgesic mechanism exist in spinal, supraspinal and peripheral sites. 
α2-adrenoceptors causes contraction of vascular and other smooth muscles 
leading to vasoconstriction and other actions like decreased bowel motility in 
gastro intestinal tract. It also causes decreased salivation, inhibition of renin 
release, increased glomerular filtration rate, decreased insulin secretion from 
pancreas, decreased platelet aggregation and decreased shivering threshold by 
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C. 
PHYSICOCHEMICAL CHARACTERISTICS 
 Dexmedetomidine is d-enantiomer of medetomidine. It belongs to 
imidazole subclass of α2 receptor agonist. It is freely soluble in water. 
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PHARMACOKINETICS 
 It is rapidly distributed and metabolized in liver, excreted in urine and 
feces. 
It undergoes metabolism through pathways of conjugation, n-methylation and 
hydroxylation. It displays nonlinear pharmacokinetics. Its pharmacokinetic 
parameters are unaltered by age, weight, or renal failure. 
Protein binding - 94% 
Elimination half life - 2 to 3 hours 
Context sensitive half time -   4 minutes after 10 minutes infusion 
     250 minutes after 8 hour infusion 
Distribution half life - <5 minutes 
 
PHARMACODYNAMICS OF DEXMEDETOMIDINE 
 Dexmedetomidine has α2: α 1 selectivity of 1600:1, so it is 8 times more 
potent α2-adrenoceptor agonist than clonidine. 
Cardio vascular system 
 Effects of dexmedetomidine on cardio vascular system are decreased heart 
rate, decreased systemic vascular resistance, decreased myocardial contractility, 
and cardiac output. 
The hemodynamic effects to bolus dose of dexmedetomidine show a 
biphasic response.  Intravenous injection of dexmedetomidine initially produces 
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increase in blood pressure and decrease in heart rate from baseline. Then 
gradually blood pressure declined below baseline. 
The incidence of hypotension and bradycardia associated with 
dexmedetomidine administration may be related to loading dose. Avoiding the 
loading dose or dose <4ug/kg reduces these side effects and transient 
hypertension can be minimized by giving the loading dose over 20 minutes. 
Younger patients with high vagal tone develop severe bradycardia and 
sinus arrest which can be effectively treated with anticholinergic agents. 
 
Respiratory system 
 Even at high doses it does not produce respiratory depression which is the 
unique feature of this drug. Hence it is widely used in ICU setup as infusion for 
the patients on mechanical ventilation. This allows daily wakeup test to assess 
their mental status and titrate sedation according to the need. So it shortens the 
duration of mechanical ventilation and reduces ICU length of stay. 
 
Central nervous system 
The CNS protective effects of dexmedetomidine not well defined. It reduces 
cerebral blood flow and CMRO2 in animal models. It has sedative, analgesic, 
anxiolytic effects due to much number of mechanisms in CNS. FDA has 
approved dexmedetomidine only for short term sedation less than 24 hr so the 
problems of tolerance, dependence, or addiction are not there. 
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Dexmedetomidine can be used for opioid detoxification, cocaine 
withdrawal, iatrogenic induced benzodiazepine and opioid tolerance. No reports 
of seizures are seen in human following dexmedetomidine administration. 
Dexmeditomidine also reduces muscle rigidity after high dose opioid. It ablates 
memory in dose dependent manner. 
 
Endocrine 
 Dexmedetomidine reduces catecholamine release so that sympathetic 
response to surgery is reduced. It increases growth hormone secretion, but no 
effects on other pituitary hormones. 
ANTAGONIST 
 α2 agonists have the advantage of their effects readily reversed by α2-
adrenergic antagonist eg: Atipamazole. Note: Atipamazole is not approved for 
human use  
ADVERSE EFFECTS 
 Hypotension 
 Hypertension 
 Nausea, vomiting 
 Bradycardia 
 Dry mouth 
 Pyrexia, chills 
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CLINICAL APPLICATIONS 
PREMEDICATION 
 Since this drug has sedative, anxiolytic, analgesic, sympatholytic, 
hemodynamic stability it can be used as adjuvant for premedication. The dose is 
0.33 to 0.67 ug/kg intravenously 15 minutes before surgery. 
INTRAOPERATIVE USE 
 It has anaesthetic sparing effect by potentiating effect of all the anaesthetic 
agents thereby reducing their requirements and related adverse effects. It reduces 
stress response of intubation, extubation and surgery and maintains hemodynamic 
stability profile intra operatively. 
REGIONAL ANAESTHESIA 
 Dexmedetomidine has high lipid solubility and penetrate nerve membrane 
rapidly. So during spinal anaesthesia blockade and peripheral nerve blockade it 
prolongs the duration of local anaesthetics. It may also be used in intravenous 
regional anaesthesia and intra articularly. 
 
PROCEDURAL SEDATION 
 Dexmedetomidine can be used for elective awake fibreoptic intubation, 
transoesophageal echocardiography, colonoscopy, shock wave lithotripsy, 
pediatric MRI. Initial loading dose 1ug/kg followed by infusion of 0.2 ug/kg/hr 
infusion. 
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ICU SEDATION 
 Dexmedetomidine produces ‘rousable’ sedation and doesnot interfere with 
respiratory drive, does not produce respiratory depression. So it helps forearly  
weaning from the ventilator, reducing the cost and length of ICU stay. 
CARDIAC SURGERY 
 Dexmedetomidine reduces the extent of myocardial ischemia and used in 
management of pulmonary hypertension in patients undergoing mitral valve 
replacement. 
NEUROSURGERY 
 Dexmedetomidine is also used in functional neuro surgery like awake 
craniotomy, implanatation of deep brain stimulators for parkinsons disease. 
MONITORED ANAESTHESIA CARE 
 It is used for sedation for monitored anaesthesia care. Average infusion 
rate to maintain BIS value of 70-80 is 0.7 ug/kg/min intra operatively. 
OPHTHALMIC SURGERY 
  It is used as premedication in patients undergoing cataract removal, 10 
minutes before surgery. 
OBESITY 
 Dexmedetomidine has narcotic sparing effect and used in morbidly obese 
patients intra operatively and post-operatively after bariatric surgery. 
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Dexmedetomidine originally approved for sedation in ICU setup, now a 
days it has many off label applications in operating room and perioperative 
environment. 
 
Availability of  dexmeditomidine 
Dexmeditomidine available as ampoule containing 1ml and 2ml solution with the 
strength of each ml containing 100mcg  
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REVIEW OF LITERATURE 
Several studies were conducted using α2 advenergic agonists as adjuvant to 
bupivacaine and other local anaesthetics for prolongation of post-operative 
analgesia. The proposed hypothesis for the mechanism of action as follows, 
            1. α2adrenoreceptors are  located on the neurons in the superficial laminae 
of the spinal cord and the locations implicated  are a) several brain stem nuclei 
implicated  in producing  analgesia b) afferent terminals of the peripheral 
neurons. α2 adrenergic agonists acts by inhibiting voltage gated Na+ and K+ 
channels and suppresses the generation of action potentials thus reduce neural 
transmission. 
           2. By release of acetylcholine inhibits the release of substance P in the 
neuraxial region. 
           3. Presynaptic activation of α2 receptor in CNS inhibits release of 
noradrenaline and terminates propagation of pain signal. 
Lipid solubility and affinity toα-adrenergic receptors are factors determining the 
duration of action of the drug. 
1.Franco CD, Vieria ZE (2000) did a study on success of subclavian 
perivascular block using a nerve stimulator. This study concluded that this 
technique provides an effective block for upper extremity surgeries. Also 
explains that the success of this block due to the fact that at injection site the 
plexus reduced to its smallest volume and sheath reduced to its smallest volume. 
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2. Brown DL (1993) did a study and analysed the various sites supraclavicular, 
interscalene, infraclavicular and axillary approaches at which brachial plexus can 
be blocked. The study concluded that supra clavicular approach produces most 
consistent anaesthesia of entire upper limb than any other technique. 
3. Winnie and Ramamoorthy
2
(1977) postulated that the brachial plexus are 
arranged so that central fibres are longest supplying the extremities of limb, the 
shorter fibres arranged more peipheraly as their area of supply is proximal. 
4.  Rachana Gandhi et al
9
 conducted study (2012) on 70 patients by comparing 
30ug dexmeditomidine added to 0.25%. Bupivacaine with control group who 
received plain 0.25% bupivacaine. Supraclavicular brachial plexus block done by 
subclavian perivascular technique. This prospective randomized study concluded 
that dexmeditomidine prolongs the duration of analgesia in supraclavicular 
brachial plexus block without any significant side effects. 
 5. Amit R. Khade
49
 et al (2013) conducted a study to evaluate the effect of 
dexmeditomidine as an adjunct to bupivacaine in brachial plexus block. The 
study was conducted on 40, ASA 1 and ASA II risk patients who were 
randomized to two groups, Group A received 20 ml 0.5% bupivacaine + 10ml 2% 
Lignocaine + 50 mcg of dexmeditomidine, group B received 0.5ml normal saline 
instead of dexmeditomidine along with above 30ml local anaesthetic. Supra 
clavicular block doneby peripheral nerve stimulator technique. This prospective 
randomized double blinded study concluded that adding 50mcg dexmeditomidine 
in supra clavicular block shortens onset of sensory andmotor block, improves 
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block quality, increases interval to first analgesic use, provides better 
hemodynamic stability, and decreases intra operative sedative requirements. 
6.SandhyaAgarwal et al
22
(2014) compared the effect of dexmeditomidine 
100mcg added to 30ml of 0.325% bupivacaine in supra clavicular brachial plexus 
block using peripheral nerve stimulator technique. This prospective randomized 
double blinded study done on 50 patients by dividing into two groups control 
groups received  30ml 0.325% bupivacaine + 1ml normal saline,Study group SD 
received 30ml 0.325% bupivacaine + 1ml (100 mcg) dexmeditomidine. The 
study concluded that dexmeditomidine as adjuvant to bupivacaine for 
supraclavicular brachial plexus block significantly shortens the onset time and 
prolongs the duration of sensory and motor blocks and duration of analgesia with 
adequate sedation and no adverse side effects. 
7.  Amany S. Ammar et al
37
 (2012) designed study to test the efficacy of adding 
dexmeditomidine to bupivacaine during placement of ultrasound guided 
infraclavicular brachial plexus block. This prospective randomized double 
blinded study done on 60 patients divided two groups, Group 1 received 30ml 
0.33% bupivacaine with 0.75mcg/kg of dexmeditomidine and group 2received 
30ml 0.33%bupivacaine with normal saline.They concluded that adding 
dexmeditomidine to bupivacaine provides 1) enhancement of onset of sensory 
and motor blockade. 2) Prolonged duration of analgesia 3) increases duration of 
sensory and motor blockade. 4) Yields lower VRS pain scores. 5) Reduces 
supplemental opioid requirements. 
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8.F.W.Abdallah et al
13
 (2013) done a systematic review and meta analysis which 
examined wheather perineural dexmeditomidine as local anaesthetic adjuvant for 
neuraxial and peripheral nerve blocks can prolong the duration of analgesia 
compared with LA alone. Five trials investigated dexmeditomidine as part of 
spinal anaesthesia and four as part of brachial plexus block. Total of 516 patients 
were analysed from nine RCTs. They summarized that dexmeditomidine is a 
potential adjuvant to LA that can exibit facilitary effect when administered 
intrathecaly or in periphery as a part of brachial plexus block. 
9.SaumyaBiswas et al
50
 (2014) evaluated the effect of combining 
dexmeditomidine with levobupivacaine with respect to duration of sensory, 
motor block and duration of analgesia. They concluded that dexmeditomidine 
added to levobupivacaine in supraclavicular brachial plexus block prolongs the 
duration of block and duration of post-operative   analgesia. 
10. Kenankaygusuzet al
12
 (2012) evaluated the effect of dexmeditomidine added 
to levobupivacaine for an axillary brachial plexus block. The study concluded 
that dexmeditomidine to axillary plexus block shortens sensory block onset time 
increases the sensory and motor block duration and time to first analgesic use and 
decreases total analgesic use with no side effects. 
11.Sarita S Swami et al
11
 conducted randomized double blinded study to 
compare dexmeditomidine and clonidine as an adjuvant to local anaesthetics in 
supra clavicular brachial plexus block. The study concluded that 
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dexmeditomidine prolongs the duration of sensory and motor block and enhances 
the quality of block as compared with clonidine. 
12.KeshavGovindRaoet al
32
 (2014) conducted a study to compare clonidine and 
dexmeditomidine as an adjuvant to supraclavicular brachial plexus block. The 
study concluded that dexmeditomidine is better and more effective as an adjuvant 
to bupivacaine in supraclavicular brachial plexus block. 
13.Yogiheesatishraopatkiet al
39
 (2015) evaluated the efficacy of 
dexmeditomidine as an adjuvant to 0.5%  ropivacaine in supra clavicular brachial 
plexus block for post-operative    analgesia. The study concluded that 
dexmeditomidine prolongs the duration of post-operative   analgesia, useful in 
early onset of sensory and motor blockade and reduced the need of analgesics in 
first 24hr post-operatively. The advantage of conscious sedation, hemodynamic 
stability and minimal side effects makes it as a potential adjuvant to peripheral 
nerve block. 
14.Harshavardhana H S et al 
40
conducted prospective randomized, double 
blinded study to compare dexmeditomidine with clonidine added to ropivacaine 
in supraclavicular nerve blocks. They concluded that when dexmeditomidine 
added to ropivacaine for brachial plexus block is a better adjuvant when 
compared to clonidine. 
15.Don Sebastian et al
42
 (2015) conducted a study to compare dexmeditomidine 
and clonidine as adjuvant to ropivacaine in supra clavicular brachial plexus block 
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and they concluded that dexmeditomidine had faster onset, greater duration of 
sensory and motor block and duration of analgesia than clonidine. 
16.VinodHosalli et al
45
 (2015) conducted randomized double blinded 
prospective study to compare dexmeditomidine and clonidine as adjuvant to 
levobupivacaine in ultrasound guided axillary brachial plexus block. They 
concluded that dexmeditomidine is more effective in prolonging the duration of 
sensory block, motor block and post-operative   analgesia compared to clonidine. 
17.Dr.SidharthSrabanRoutrayet al
20
 studied the effects of clonidine on 
ropivacaine in supraclavicular brachial plexus block. They concluded that 
clonidine added to ropivacaine increases the onset and duration of sensory and 
motor block. 
18.Yu Zhang et al 
46
(2014)conducted a study  by adding dexmeditomidine 
100mcg to ropivacaine in axillary brachial plexus block. They concluded that 
dexmeditomidine added to ropivacaine prolongs the duration of block. However 
it may also lead to side effects such as bradycardia, hypotension, and 
hypertension. 
19.VaniaKanvee et al (2015) conducted a comparative study of clonidine and 
dexmedetomidine as an adjuvant with ropivacaine in supraclavicular brachial 
plexus block for upper limb surgeries. The study concluded that the duration of 
sensory, motor blockade and post-operative   analgesia was significantly 
prolonged by dexmeditomidine without significant hemodynamic alterations. 
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MATERIALS AND METHODS 
This study was carried out in the orthopaedic surgery theatre, Kanyakumari 
government medical college after obtaining institutional ethical committee 
approval. 
 
AIM: 
 To compare the effect of three different dose of dexmeditomidine as 
adjuvant to bupivacaine in supra clavicular brachial plexus block in terms of  
 Onset and duration of sensory block 
 Onset and duration of motor block 
 Duration of analgesia 
 Peri operative hemodynamics 
 Complications 
 
Study design 
 This was a randomized, prospective, double blinded study. 
 The study has started after receiving Institutional Ethical Committee 
approval and informed written consent from all the patients. 
Randomisation 
 Simple randomized sampling was done by computer generated random 
numbers. 
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Sample Size 
 Sixty patients were studied. 
Group allocation 
 Patients were allocated into three groups, 
 Group A(n-20) – 30 ml 0.33% bupivacaine + dexmeditomidine 50mcg 
 Group B(n-20) – 30ml 0.33% bupivacaine + dexmeditomidine 75mcg 
 Group C (n-20) – 30ml 0.33% bupivacaine + dexmeditomidine 100mcg 
Masking 
 The anaesthesiologist who administered the drug and the observer were 
blinded to the study. Local anaesthetic, study drug mixture was prepared by 
another anaethesiologist not participating in the study. The intra operative 
monitoring and post-operative   observation was done by the same 
anaesthesiologist who administered the drug, who was unaware of the group 
allocation 
Inclusion Criteria 
 Age – 20-60 years 
 Weight – 50-70 kg 
 ASA I & II 
Written informed consent 
Upperlimb orthopedic surgeries 
Exclusion Criteria 
 Consent not given 
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 Significant neurological disease 
 Psychiatric disorder 
 Pregnancy and lactation 
Patients on anticoagulation 
Significant systemic disorder 
Known hypersensitivity to study drugs 
Patients on adrenergic drugs 
 
Materials 
Sterile tray for regional block 
 Drugs for the block 
  Equipment & drugs for resuscitation 
 
Preparation of study drug 
Bupivacaine is prepared as 30ml of 0.33% solution by adding 10ml 
distilled water to 20ml of 0.5% bupivacaine. Dexmeditomidine is prepared by 
taking the drug in insulin syringe .40 units syringe equalent to1ml - 40 units equal 
to 100µg, 30 units equal to 75µg, and 20 units equal to 50µg 
Methods 
Pre Operative Preparation 
 Patients were pre operatively assessed and procedure was explained to the 
patient regarding the technique and consent obtained. 
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Conduct of anaesthesia 
 On arrival of the patient in the operating room, monitors like pulse 
oximeter, non invasive blood pressure and ECG were connected and baseline 
values recorded. An intra venous access was obtained in the opposite arm. 
Supraclavicular brachial plexus block 
 Patient were positioned supine with the head turned away from the side to 
be blocked and the ipsilateral arm adducted. The neck was prepared with 
povidone iodine solution and draped with sterile towels. 
Supraclavicular brachial plexus block was done by subclavian perivascular 
technique – paraesthesia technique. 
Procedure 
 A line was drawn laterally from the cricoids cartilage to cross the 
sternomastoid at its midpoint. The interscalene groove was located behind the 
midpoint of posterior border the muscle. Then the groove was followed distally 
towards the clavicle. Approximately 1-1.5cm above the midpoint of the clavicle, 
the pulsation of subclavian artery was made out in the interscalene groove. 
Under strict aseptic precautions after local infiltration of 2% lignocaine, a 
22G short beveled needle is inserted in the interscalene groove 1 to 1.5 cm above 
the clavicle and directed towards ipsilateral nipple posteriorly and caudally. After 
elicitation of paraesthesia the local anaesthetic drug mixture injected after 
repeated aspiration. 
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Evaluation of block 
The following observations were made; 
 Vital signs monitoring -heart rate, non-invasive blood pressure, oxygen 
saturation and sedation score were measured every minute for the first 5 
minute and every 5 minutes for 1 hour, every 15 minutes thereafter until 
the end of surgery& in the post-operative   period. For statistical purposes 
they were documented at 0,5,10,15,30,45,60,90,120,150 minutes. 
 Immediately following the administration of the drug, patient was 
evaluated for the onset of sensory and motor blockade every minute. 
 Onset time for sensory block – time from completion of injection to loss of 
cold and pain sensation (score 2) 
o Loss to cold sensation using alcohol swab in all dermatomes of 
brachial plexus. 
o Atraumatic pin prick test 
 Score 0 – normal sensation 
 Score 1 : loss of sensation to pin prick 
 Score 2 : loss of sensation to touch 
 Onset time for motor block-Time from completion of injection to complete 
motor blockade with inability to move fingers 
Modified bromage scale 
o Score 0 – normal motor function with full flexion, extension of 
elbow, wrist and fingers. 
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o Score 1 – decrease motor strength with ability to move fingers 
and/or wrist only 
o Score 2 – complete motor blockade with inability to move fingers. 
 
 Sedation was assessed by modified ramsay sedation scale .The scale isas 
follows 
o 1 = anxious, agitated, restless; 
o 2 =cooperative, oriented, tranquil; 
o 3 = responds to commands only; 
o 4 = brisk response to light glabellar tap or loud noise; 
o 5 = sluggish response to light glabellar tap or loud noise; 
o 6 =no response. 
Only patients with complete sensory & motor blockade are included in the 
study. Failure of block to be established even after 20 minutes was taken as block 
failure. Block failure patients managed with local anaesthetic supplementation or 
general anaesthesia as appropriate and those patients excluded from the study. 
Sedation is assessed using Ramsay Sedation score and  if the patient is 
anxious even 1 hr after blocking the plexus, 1mg midazolam was given to achieve 
a sedation score of 2-3.When the saturation falls  below 92%  supplemental o2 
was given. 
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Patients were monitored for local anaesthesic toxic reactions including 
subjective and objective manifestations like circumoral numbness, tinitus, 
twitching, and convulsions. 
Patients were also monitored for complications associated with the 
technique, drug like intravascular injection, Intrathecal injection, pneumothorax, 
hypotension & bradycardia. 
Post-operative  ly heart rate, NIBP, Oxygen saturation, sedation score 
recorded at 0,30,60 min, 2 hr, 3 hr, 4 hr, 6 hr, 12 hr, 24 hr. 
 
 Duration of sensory block – time from injection of localanaesthetic to 
complete recovery from cold and pain sensation in all dermatomes. 
 Duration of motor block – time from injection of local anaesthetic to 
complete recovery of motor function modified bromage scale score 0. 
 Duration of Analgesia – time from onset of sensory block to vas score 4. 
VAS Score 
o 0 – No pain 
o 3 – Mild pain 
o 5 – Moderate pain 
o 10 – Most severe pain 
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Inj. Diclofenac 75mg intramuscularly is given as a rescue analgesic when 
the pain score is more than 4. 
 Patients were followed for upto 24 hrs for any adverse effects  
o Bradycardia – heart rate <60 beats / minute and treated with 
inj.atropine 10-20 µg/kg 
o Hypotension – 20% decrease from baseline value and treated with 
IV fluid bolus and inj.ephedrine 6mg IV in incremental boluses. 
o Sedation 
o De-Saturation 
o Nausea and vomiting 
o Dizziness, Pruritis 
o Arrhythmia 
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OBSERVATION & RESULTS 
 
Statistical Tools  
The information collected regarding all the selected cases were recorded in 
a Master Chart. Data analysis was done with the help of computer using 
Epidemiological Information Package (EPI 2010) developed by Centre for 
Disease Control, Atlanta.  
Using this software range, frequencies, percentages, means, standard 
deviations, chi square , ’F’ value and   'p'  values were calculated.  ANOVA test 
was used to test the significance of difference between quantitative variables and 
Yate’s and Fisher’s chi square tests for qualitative variables. A 'p' value less than 
0.05 is taken to denote significant relationship. 
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RESULTS 
Group A ; Dexmed 50 mcg 
Group B ; Dexmed 75 mcg 
Group C ; Dexmed 100 mcg 
 
A:PROFILE OF CASES STUDIED 
Table A1 :    Age distribution 
 
Age group 
Group A Group B Group C 
No. % No. % No. % 
Up to 30 yrs 9 45 8 40 9 45 
31 – 40 yrs 5 25 4 20 3 15 
41 – 50 yrs 1 5 2 10 2 10 
51 – 60 yrs 5 25 6 30 6 30 
Total 20 100 20 100 20 100 
Range 
Mean 
S.D. 
20 – 60 yrs 
36.1 yrs 
13.8 yrs 
22 – 60 yrs 
39.5 yrs 
13.8 yrs 
22 – 60 yrs 
39.2 yrs 
13.9 yrs 
‘p’ 0.6898 Not significant 
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The three groups were matched according to their age for randomization 
and found that there was no statistical difference between the mean ages between 
them (36.1±13.8 ≈ 39.5±13.8 ≈ 39.2±13.9 and P >0.05) 
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Table A 2 :   Sex distribution 
Matching of three groups according to their  sex 
 
Sex 
Group A Group B Group C 
No. % No. % No. % 
Male 13 65 10 50 11 55 
Female 7 35 10 50 9 45 
Total 20 100 20 100 20 100 
‘p’ value 
between 
Group A &B 
Group A & C 
Group B & C 
 
 
0.5224 Not significant 
0.7469 Not significant 
1.0 Not significant 
 
The three groups were matched according to their sex and found that there 
was no significant   statistical difference between them 
 
 
 
58 
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Table A3 : Weight 
Matching of three groups according to their weight 
 
 
Parameter 
Weight (kgs) 
Group A Group B Group C 
Range 48 – 65  45 - 65 45 – 65 
Mean 55.8 56.2 56.2 
S.D. 5.3 5.7 6.5 
‘p’ 0.9726 Not significant 
The three groups were matched according to their weight and found that there 
was no difference between them (55.8±5.3 ≈ 56.2±5.7 ≈ 56.2±6.5 and P >0.05)
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Table A4 :  Duration of Surgery 
 
Parameter 
Duration of Surgery (minutes) 
Group A Group B Group C 
Range 70 – 150 60 – 150 70 – 150 
Mean 104.0 103.0 104.0 
S.D. 22.5 25.5 22.5 
‘p’ 0.9881 Not significant 
The three groups were matched according to the duration of surgery & 
found that there is no statisticaly significant difference between them (104±22.5≈ 
103±25.5≈104±22.5andP>0.05)
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B :   COMPARATIVE EFFICACY OF THE THREE DOSES 
Table B1 :   Sensory Block onset 
 
Parameter 
Sensory Block onset (minutes) 
Group A Group B Group C 
Range 10 - 22 10 - 18 5 – 10 
>Mean 16.3 12.4 7.35 
S.D. 3.31 2.5 1.5 
‘p’ value between 
Group A & Group B 
Group A & Group C 
Group B & Group C 
 
< 0.0001 Significant 
< 0.0001 Significant 
< 0.0001 Significant 
 
 Table B1 shows the comparison of onset of sensory blockade between the 
three groups .The mean onset time of group A was significantly longer than 
group B which was significantly longer than group C. A (16.3±3.31) >B(12.4±2.5) 
>C(7.35±1);  
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Table B2:   Motor Block onset 
 
Parameter 
Motor Block onset (minutes) 
Group A Group B Group C 
Range 15 - 24 12 - 22 8 – 18 
Mean 20.4 16.15 12.15 
S.D. 2.7 2.89 2.81 
‘p’ value between 
Group A & Group B 
Group A & Group C 
Group B & Group C 
 
< 0.0001 Significant 
< 0.0001 Significant 
< 0.0001 Significant 
 
Table B2 shows the comparison of onset of motor blockade between the 
three groups. The mean onset time of group A was significantly longer than 
group B which was significantly longer than group C. A(20.4±2.7) 
>B(16.15±2.89) >C(12.15±2.81) 
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Table B3 :   Sensory Block Duration 
 
Parameter 
Sensory Block Duration (minutes) 
Group A Group B Group C 
Range 300 - 560 450 - 740 620 – 800 
Mean 432.5 625.5 722.5 
S.D. 69.8 72.7 55.1 
‘p’ value between 
Group A & Group B 
Group A & Group C 
Group B & Group C 
 
< 0.0001 Significant 
< 0.0001 Significant 
< 0.0001 Significant 
 
Table- B3 shows the comparison of duration of sensory blockade between 
the three groups. The mean duration of sensory block of group C was 
significantly longer than  group B and group B was significantly longer than 
group A. C(722.5±55.1) >B(625.5±72.7) >A(432.5±69.8) 
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Table B 4:   Motor Block Duration 
 
Parameter 
Motor Block Duration (minutes) 
Group A Group B Group C 
Range 270 - 580 360 - 720 620 – 800 
Mean 426.5 604.5 704.5 
S.D. 81.8 98.6 41.4 
‘p’ value between 
Group A & Group B 
Group A & Group C 
Group B & Group C 
 
< 0.0001 Significant 
< 0.0001 Significant 
< 0.0001 Significant 
 
The duration of motor block shown in the above table B 4 . The duration of 
motor block of group C was significantly higher than group B and group B was 
significantly higher than group A. C(704.5±41.4) > B (604.5±98.6) > A 
(426.5±81.8) 
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Table B 5:   Duration of Analgesia 
 
Parameter 
Duration of Analgesia (minutes) 
Group A Group B Group C 
Range 330 - 610 460 - 780 620 – 820 
Mean 480.5 642.0 736.5 
S.D. 81.3 76.5 67.1 
‘p’ value between 
Group A & Group B 
Group A & Group C 
Group B & Group C 
 
< 0.0001 Significant 
< 0.0001 Significant 
< 0.0001 Significant 
 
The duration of analgesia between the three groups were 
480±81.3,642±76.5 and 736±67.1 minutes respectively. The mean duration of 
analgesia of C group was significantly longer than the B group and B group was 
significantly longer than the A group .C (736±67.1)>B(642±76.5)>A(480±81.3)  
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Table B6:   Sedation Score 
 
Parameter 
Sedation Score 
Group A Group B Group C 
Range 1 - 5 2 - 6 3 – 6 
Mean 2.95 3.8 4.65 
S.D. 1.05 1.15 10.4 
‘p’ value between 
Groups A,B and C 
Group A & Group B 
Group A & Group C 
Group B & Group C 
 
< 0.0001 Significant 
0.0195 Significant 
< 0.0001 Significant 
0.019 Significant 
 
The sedation score of three groups are compared in table B6.The C group 
achieved more sedation level than group B and group B achieved more sedation 
level than group A. C(4.65±10.4)>B(3.8±1.15)> A (2.95±1.05 ) 
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Table B 7:    Complications 
 
Complications 
Group A Group B Group C 
No. % No. % No. % 
Hypotension - - 2 10 1 5 
Bradycardia 1 5 3 15 4 20 
Cases with 
complications 
1 5 5 25 5 25 
Cases without 
complications 
19 95 15 75 15 75 
‘p’ value between 
Group A & Group B 
Group A & Group C 
Group B & Group C 
 
0.1818 Not significant 
0.1818 Not significant 
1.0  Not significant 
 
The above table compares the adverse effects between three groups 
.Bradycardia and Hypotension were the only adverse effects noted and was much 
associated with the group C.But the association within the groups did not have 
any statistical significance( P>0.05) 
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C : HEMODYNAMIC STABILITY 
Table C1  : Changes in Pulse Rate 
Pulse 
rate at 
Group A Group B Group C ‘p’ Significance 
Mean S.D. Mean S.D. Mean S.D. 
INTRA OPERATIVE 
0 min. 85.9 7.3 86.0 6.2 86.6 11.5 0.9564 Not significant 
5 min. 87.5 7.2 87.1 7.5 88.1 11.7 0.9342 Not significant 
10 min. 89.1 7.5 87.1 8.7 86.6 13.1 0.701 Not significant 
15 min. 87.9 7.3 85.0 8.2 87.8 17.3 0.6807 Not significant 
30 min. 85.3 7.7 83.1 11.5 86.7 18.5 0.6982 Not significant 
45 min. 83.2 9.4 81.9 13.9 87.2 19.5 0.5046 Not significant 
60 min. 82.2 9.8 81.5 13.3 84.6 15.9 0.7395 Not significant 
90 min. 81.8 8.4 81.6 11.2 84.9 12.6 0.5721 Not significant 
120 min. 81.2 8.4 83.5 9.7 83.6 11.7 0.6833 Not significant 
150 min. 81.0 8.5 84.4 8.7 85.5 11.3 0.3091 Not significant 
POST-OPERATIVE   
0 min. 84.1 6.3 84.5 10.9 83.2 5.8 0.8782 Not significant 
15 min. 85.9 6.6 86.0 10.9 84.3 5.4 0.7663 Not significant 
30 min. 86.9 7.0 86.5 10.9 85.0 5.4 0.7516 Not significant 
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1 hour 86.7 5.6 86.4 11.7 84.9 5.0 0.7494 Not significant 
2 hrs. 86.8 5.3 86.4 11.9 84.3 5.2 0.5869 Not significant 
3 hrs. 85.4 6.4 87.0 12.6 83.0 5.6 0.3645 Not significant 
4 hrs. 83.9 8.0 85.3 11.6 81.8 6.7 0.479 Not significant 
6 hrs. 85.0 6.8 84.4 8.5 83.6 6.2 0.8282 Not significant 
12 hrs. 85.3 5.1 84.2 8.4 84.0 4.6 0.7799 Not significant 
24 hrs. 85.7 4.8 85.4 8.0 84.5 4.9 0.8097 Not significant 
 
The pulse rate at different intervals in intra operative and post-operative   
periods are shown in table C1 .The mean pulse rate at the above different times 
between the three groups are not statistically significant(P>0.05) 
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Table C2  : Changes in Systolic Blood Pressure 
 
Sys. 
B.P. at 
Group A Group B Group C ‘p’ Significance 
Mean S.D. Mean S.D. Mean S.D. 
INTRA OPERATIVE 
0 min. 124.0 9.7 123.4 9.1 121.5 10.9 0.7091 Not significant 
5 min. 122.8 9.2 122.5 10.5 121.0 10.2 0.8393 Not significant 
10 min. 121.5 9.2 117.1 11.4 118.5 9.3 0.3723 Not significant 
15 min. 119.1 10.0 114.4 11.0 115.0 9.5 0.2937 Not significant 
30 min. 118.4 9.1 113.6 10.7 113.5 11.0 0.2189 Not significant 
45 min. 114.9 9.4 113.1 10.0 112.5 10.7 0.7424 Not significant 
60 min. 112.0 7.4 110.9 9.9 110.0 10.8 0.8086 Not significant 
90 min. 115.7 7.5 112.9 9.7 112.0 12.8 0.5027 Not significant 
120 
min. 
112.8 6.4 111.4 8.6 108.0 15.1 0.3524 Not significant 
150 
min. 
112.7 6.8 111.1 8.1 109.5 16.4 0.6782 Not significant 
POST-OPERATIVE   
0 min. 107.6 15.4 109.5 11.9 110.0 11.7 0.8299 Not significant 
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15 min. 111.0 11.7 109.5 9.8 109.3 10.0 0.871 Not significant 
30 min. 111.3 14.8 110.7 12.1 110.2 12.4 0.9656 Not significant 
1 hour 111.3 14.8 111.0 12.5 110.5 12.8 0.982 Not significant 
2 hrs. 108.4 5.0 109.0 9.7 109.5 9.4 0.9376 Not significant 
3 hrs. 107.5 7.9 108.5 9.3 109.0 9.1 0.8604 Not significant 
4 hrs. 109.1 9.5 109.3 10.0 109.8 9.8 0.9731 Not significant 
6 hrs. 109.1 9.5 109.3 10.5 109.8 10.3 0.9749 Not significant 
12 hrs. 108.4 9.7 109.1 10.4 108.9 9.5 0.974 Not significant 
24 hrs. 108.8 9.7 109.8 9.8 109.3 9.5 0.9527 Not significant 
The systolic blood pressure at different intervals in intra operative and 
post-operative   periods are shown in table C2 .The mean systolic blood pressure 
at the above different times between the three groups are not statistically 
significant. 
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Table C3  : Changes in Diastolic Blood Pressure 
Dias. 
B.P. at 
Group A Group B Group C ‘p’ Significance 
Mean S.D. Mean S.D. Mean S.D. 
INTRA OPERATIVE 
0 min. 78.6 7.8 78.1 8.6 78.2 8.0 0.9753 Not significant 
5 min. 74.9 5.4 74.3 6.4 74.8 5.5 0.9403 Not significant 
10 min. 73.0 6.8 73.0 6.8 72.6 7.7 0.9791 Not significant 
15 min. 69.2 6.1 69.4 5.9 68.9 6.9 0.9687 Not significant 
30 min. 68.4 5.8 68.9 6.5 68.5 6.5 0.9721 Not significant 
45 min. 68.5 6.1 69.0 5.7 68.8 6.9 0.9584 Not significant 
60 min. 67.9 6.1 68.4 5.8 67.9 6.9 0.9562 Not significant 
90 min. 70.2 8.2 74.5 9.8 74.9 9.6 0.2124 Not significant 
120 min. 71.9 7.0 73.4 9.0 73.5 8.9 0.8066 Not significant 
150 min. 73.1 6.0 72.1 8.6 71.9 8.8 0.8759 Not significant 
POST-OPERATIVE   
0 min. 66.4     6.3 68.7 8.5 69.7 9.5 0.4336 Not significant 
15 min. 67.7 7.1 67.0 10.5 69.3 9.7 0.7222 Not significant 
30 min. 71.6 7.9 71.9 9.9 72.4 8.5 0.9533 Not significant 
1 hour 71.4 6.8 71.9 4.8 70.9 7.8 0.8914 Not significant 
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2 hrs. 71.8 6.0 71.5 5.6 70.8 9.2 0.8906 Not significant 
3 hrs. 73.5 6.3 71.9 6.2 70.7 13.9 0.6485 Not significant 
4 hrs. 72.7 6.7 72.8 6.7 69.1 8.9 0.2166 Not significant 
6 hrs. 72.7 5.9 71.6 6.5 72.8 8.1 0.8236 Not significant 
12 hrs. 73.1 5.7 73.1 5.4 72.9 8.2 0.995 Not significant 
24 hrs. 73.5 5.8 73.8 4.8 72.4 8.3 0.7563 Not significant 
 
The diastolic blood pressure at different intervals in intra operative and 
post-operative   periods are shown in table C3 .The mean diastolic  blood 
pressure at the above different times between the three groups are not statisticaly 
significant (P>0.05) 
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Table C4  : Changes in SPO2 
 
    
SPO2 
at 
Group A Group B Group C ‘p’ Significance 
Mean S.D. Mean S.D. Mean S.D. 
INTRA OPERATIVE 
0 min. 99.9 0.31 99.85 0.37 99.85 0.37 0.8717 Not significant 
5 min. 99.45 0.69 99.4 0.68 99.7 0.57 0.3 Not significant 
10 min. 99.1 0.79 99.15 0.81 99.35 0.75 0.5678 Not significant 
15 min. 99.25 0.79 99.3 0.73 99.45 0.76 0.6887 Not significant 
30 min. 99.45 0.69 99.4 0.68 99.25 0.97 0.7077 Not significant 
45 min. 99.85 0.37 99.8 0.41 99.65 0.49 0.309 Not significant 
60 min. 99.55 0.69 99.6 0.68 99.75 0.44 0.5663 Not significant 
90 min. 99.8 0.41 99.75 0.55 99.85 0.37 0.7813 Not significant 
120 min. 100.0 0.0 99.95 0.22 99.75 0.51 0.1003 Not significant 
150 min. 100.0 0.0 99.95 0.22 99.85 0.37 0.1589 Not significant 
 
The SPO2 at different intervals in intra operative and post-operative   
periods are shown in table C4 .The mean SPO2 at the above different times 
between the three groups are not statistically significant(P>0.05) 
82 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
83 
 
DISCUSSION 
Several researches have revealed that the administration of an α2 
adrenergic agonist in the peripheral nerve blockade produces prolonged post-
operative   analgesia without much complications. Several mechanism have been 
hypothesized to explain the analgesic effect of α2 adrenergic agonist including 
complex interaction with axonal ion channels which  result in direct suppression 
of impulse propagation ,vasoconstriction around injection site and local release of 
encephalin like substances. 
Studies have shown that clonidine when added to bupivacaine in brachial 
plexus block prolongs the duration of analgesia but was associated with side 
effects such as hypotension, bradyardia and respiratory depression.  Several 
animal studies have been investigated the effect of dexmeditomidine as adjunct to 
local anaesthetics. Brummet &colleagues reported that dexmeditomidine added to 
ropivacaine in sciatic nerve block provided prolonged analgesia than systemic 
administration. Another study conducted by Brummett and colleagues discovered 
that dexmeditomidine added to bupivacaine prolong sensory & motor block 
duration however it alone failed to show significant sensory & motor blockade. 
Recently there are several study available using dexmeditomidine as 
adjunct to various local anaesthetics in central neuraxial blockade and 
peripheralnerve blockade. There are many studies available with various dose of 
dexmeditomidine as adjuvant to local anaesthetics  in supra clavicular brachial 
plexus block . In our study we designed to compare the three doses 
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50µg,75µg,100µg of dexmeditomidine to know the optimal dose in supra 
clavicular brachial plexus block for upper limb orthopedic surgeries. 
Demographic characters like age, sex, weight, duration of surgery 
comparable in all three groups.In our study we observed that sensory block onset 
was longer in group A (16.3±3.31)than group B(12.4±2.5) which is longer than 
group C (7.35±1)(table B1) and motor block onset also longer in group A 
(20.4±2.7) than group B (16.15±2.89) which is longer than group C(12.15±2.81) 
(table B2) .So we conclude that onset of sensory &motor blockade was earlier as 
the dose increases.These observations were comparable with Agarwal S etal
22
 ,in 
their study earlier onset of blockade with 100µg dexmeditomidine  but  different 
from Yu zhang et al
46
, in their study there is no significant difference in sensory 
and motor block onset between dexmeditomidine 50µg and 100µg group. 
The duration of both sensory and motor block was longest  with group C 
(sensory mean 722.5±55.1minutes, motor mean 704±41.4minutes) compared 
with group B (sensory mean 625.5±72.7 minutes , motor mean 604±98.6 
minutes) which is longer than group A (sensory mean 432±69.8minutes, motor 
mean 426.5±81.8).So we conclude that sensory & motor block duration is longer 
as the dose increases .This observation is comparable with  previous studies Yu 
zhang et al 
46
 who observed  the duration of sensory and motor block significantly 
differ between groups and Agarwal S et al
22
. The mean duration of analgesia was 
dose dependent (tableB5) with C (736±67.1) >B(642±76.5) > 
A(480.5±81.3)minutes. This is also comparable with the other studies Yu zhang 
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et al
46
,Agarwal S et al 
22
and Amany S Ammar
37
.The sedation was also (table B6) 
dose dependent  with group C achieved more sedation than group B who 
achieved more sedation than group A. C(4.65±10.4) > B(3.8±1.15) > 
A(2.95±1.05 ) In respect of complications bradycardia and hypotension were the 
only adverse effects noted and was much associated with the group C.But the 
association within the groups did not have any statistical significance( P>0.05). 
This observation is coinciding with SawmyaBiswas et al
50
 and SandhyaAgarwal 
et al
22
 but differ from yu Zhang et al
46
. The statistical analysis of intra operative 
and post-operative   hemodynamic variables such as PR,SBP,DBP,SPO2 between 
the three groups  showed no statistical significant hemodynamic fluctuation. 
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SUMMARY 
To summarise, dexmeditomidine added to bupivacaine in supraclavicular 
brachial plexus block had a dose dependent effect on the sensory and motor block  
charecteristics showing  
 
1. Earlier onset of sensory and motor blockade 
2. Increased duration of sensory and motor blockade 
3. Increased duration of post-operative   analgesia 
4. Increased level of sedation 
 
Three different doses 50,75,100µg did not vary in their effect on the 
hemodynamic stability and adverse effects. 
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CONCLUSION 
 
Dexmeditomidine ,added to bupivacaine in supra clavicular brachial plexus 
block  for upper limb orthopedic surgeries , has a dose dependent effect on the 
sensory and motor blockade , with earlier onset and increased duration of 
blockade and prolonged post-operative   analgesia , gives better level of sedation 
and provides  stable hemodynamic control during the intra operative period. 
 
Dexmeditomidine 100µg is an optimal dose to provide prolonged post-
operative   analgesia without significant side effects 
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PROFORMA 
COMPARISON OF THREE DIFFERENT DOSES OF 
DEXMEDITOMIDINE AS ADJUVANT TO BUPIVACAINE IN 
SUPRA CLAVICULAR BRACHIAL PLEXUS BLOCK FOR 
UPPER LIMB ORTHOPAEDIC SURGERIES 
Date  : 
Name  :   Age/sex :   IP no: 
Height :   Weight :  ASA risk: 
Diagnosis :     Plan of surgery: 
Duration of surgery:                   
Plan of anaesthesia   : 
Pre anaesthetic status: 
PR:                    BP:                            RR: 
CVS:        RS: 
Procedure:-Supraclavicular block 
30ml 0.33% 
bupivacaine  with 
dexmeditomidine 
50µg 
 30ml 0.33% 
bupivacaine with 
dexmeditomidine 75µg 
 30ml 0.33% 
bupivacaine with 
dexmeditomidine 
100µg 
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Monitoring 
Time of performance of 
block 
Sensory block onset Motor block onset 
   
 
Monitors PR(bpm) BP(mm 
hg) 
RR SpO2(%) Sensory 
block grade 
Motor 
block grade 
Sedation 
score 
0min        
5min        
10min        
15min        
30 min        
45min        
60min        
90min        
120min        
150min        
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Post-operative   monitoring 
Time PR BP RR Spo2 Sensory 
block grade 
Motor block 
grade 
Sedation 
score 
0min        
15min        
30min        
1hr        
2hr        
3hr        
4hr        
5hr        
6hr        
7hr        
8hr        
9hr        
10hr        
11hr        
12hr        
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18hr        
24hr        
 
Time of reversal of sensory block  -- 
Time of reversal of motor block -- 
Time of C/o moderate pain (VAS4) & Rescue analgesia -- 
Duration of sensory block -- 
Duration of motor block – 
Duration of analgesia – 
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Master Chart 
S.No 
GROUP 
Age Weight ( kg ) Sex Duration of surgery  (min) 
1 A 60 50 M 140 
2 A 32 55 F 70 
3 A 23 58 F 100 
4 A 38 62 M 80 
5 A 40 55 M 90 
6 A 45 65 M 100 
7 A 38 48 F 95 
8 A 56 52 F 120 
9 A 20 56 F 90 
10 A 55 62 M 90 
11 A 22 60 M 140 
12 A 26 52 M 110 
13 A 23 50 M 100 
14 A 31 51 M 130 
15 A 25 54 F 95 
16 A 27 65 M 150 
17 A 28 62 M 80 
18 A 21 54 F 80 
19 A 55 50 M 120 
20 A 56 55 M 100 
21 B 35 62 F 80 
22 B 60 60 M 100 
23 B 30 55 M 70 
24 B 23 58 F 90 
25 B 28 50 F 90 
26 B 55 65 M 95 
27 B 60 45 F 120 
28 B 22 65 M 60 
29 B 28 48 M 90 
30 B 26 56 M 140 
31 B 38 60 F 100 
32 B 45 50 F 150 
33 B 40 55 F 120 
34 B 32 52 M 95 
35 B 55 57 M 150 
36 B 58 52 F 80 
37 B 46 60 F 90 
38 B 26 65 M 120 
39 B 25 54 M 90 
101 
 
40 B 57 55 F 130 
41 C 30 52 M 70 
42 C 46 50 F 100 
43 C 30 65 F 80 
44 C 23 58 M 90 
45 C 60 50 M 100 
46 C 25 65 F 95 
47 C 60 45 F 120 
48 C 22 56 M 90 
49 C 28 57 M 90 
50 C 57 65 F 140 
51 C 38 58 M 110 
52 C 45 60 F 100 
53 C 58 55 F 130 
54 C 32 52 M 95 
55 C 55 48 M 150 
56 C 40 62 F 80 
57 C 28 60 M 80 
58 C 26 46 F 120 
59 C 55 54 M 100 
60 C 26 65 m 140 
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S.N
o GROU
P 
INTRA OPERATIVE PULSE RATE(BEATS PER MINUTE) 
0 
min 
5 
Min 
10 
min 
15 
min 
30 
min 
45 
min 
60 
min 
90 
min 
120 
min 
150 
min 
1 A 88 88 89 86 89 91 86 88 94 90 
2 A 88 90 90 88 86 82 88 76 76 77 
3 A 80 88 90 86 87 90 92 84 76 84 
4 A 88 80 84 89 85 84 76 87 84 85 
5 A 82 78 72 71 68 62 58 55 56 62 
6 A 84 86 88 96 91 93 94 85 86 89 
7 A 82 84 87 78 73 73 70 74 73 73 
8 A 86 91 82 78 73 68 68 86 80 84 
9 A 82 86 96 90 90 88 86 80 88 76 
10 A 86 89 91 91 87 86 78 76 78 76 
11 A 98 91 97 90 88 86 86 90 88 86 
12 A 92 97 99 96 92 89 85 84 91 97 
13 A 84 99 89 87 78 76 75 82 80 70 
14 A 90 78 80 88 86 78 82 84 82 78 
15 A 80 78 80 85 89 80 90 81 81 87 
16 A 106 102 106 100 98 97 97 96 90 92 
17 A 78 76 89 78 76 72 74 76 76 74 
18 A 73 93 90 89 86 82 80 78 74 72 
19 A 89 89 90 94 92 90 88 86 84 82 
20 A 81 87 93 97 92 96 90 88 86 85 
21 B 88 88 89 86 89 91 86 88 94 90 
22 B 88 90 90 88 86 82 88 77 77 76 
23 B 88 88 90 90 80 87 90 96 84 89 
24 B 80 80 84 89 85 84 76 84 85 87 
25 B 84 86 87 80 82 76 72 80 86 89 
26 B 82 80 72 70 56 54 55 64 66 67 
27 B 86 86 88 78 73 73 70 74 70 74 
28 B 82 84 82 78 73 68 68 80 86 85 
29 B 86 91 96 90 88 90 92 66 70 77 
30 B 82 96 91 87 91 93 92 85 84 88 
31 B 92 90 89 88 94 90 85 87 94 98 
32 B 98 98 99 99 96 92 89 98 91 97 
33 B 90 94 97 87 85 89 98 87 92 90 
34 B 84 80 83 87 89 93 88 94 94 85 
35 B 80 78 80 85 89 84 90 80 87 87 
36 B 100 104 106 98 95 99 102 98 96 94 
37 B 73 74 75 70 62 54 67 65 76 81 
38 B 86 89 87 90 94 88 83 88 89 81 
39 B 81 87 85 88 90 94 84 79 84 85 
40 B 89 78 72 71 65 56 54 62 65 67 
41 C 85 89 91 87 92 95 86 88 87 89 
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42 C 90 94 98 99 96 98 104 88 89 94 
43 C 108 110 104 114 116 122 113 102 101 104 
44 C 86 86 88 86 84 80 86 85 71 79 
45 C 96 98 99 110 104 99 92 96 96 92 
46 C 84 87 80 91 85 94 86 82 88 93 
47 C 70 68 60 52 48 63 62 73 71 75 
48 C 76 78 65 58 56 56 62 64 65 67 
49 C 82 94 84 82 94 96 86 94 86 85 
50 C 92 92 94 93 95 98 102 87 85 87 
51 C 106 106 107 106 101 104 93 96 98 96 
52 C 80 85 88 89 85 83 93 91 89 89 
53 C 97 94 96 105 106 102 94 95 93 90 
54 C 86 80 74 65 57 51 56 62 67 68 
55 C 78 84 86 85 88 83 87 86 84 87 
56 C 75 77 78 85 88 94 87 80 85 91 
57 C 106 109 104 107 104 101 90 94 93 99 
58 C 74 72 70 65 58 47 52 54 57 59 
59 C 89 82 86 95 92 97 83 91 82 85 
60 C 72 77 79 81 84 80 77 89 85 80 
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S.N
o GROU
P 
INTRA OPERATIVE SYSTOLIC B.P.(MM HG) 
0 
min 
5 
Min 
10 
min 
15 
min 
30 
min 
45 
min 
60 
min 
90 
min 
120 
min 
150 
min 
1 A 130 130 130 132 126 120 114 115 110 110 
2 A 126 126 126 130 126 122 114 115 114 110 
3 A 140 140 140 130 130 128 96 128 124 130 
4 A 120 120 120 130 126 122 116 124 118 120 
5 A 140 140 138 130 130 136 126 120 116 112 
6 A 120 114 118 114 108 104 120 116 112 110 
7 A 130 124 124 120 120 117 120 98 96 98 
8 A 124 126 120 120 112 108 106 116 114 118 
9 A 136 137 132 139 138 130 117 124 119 106 
10 A 110 112 108 106 114 108 106 116 109 109 
11 A 120 124 118 114 118 110 108 108 110 110 
12 A 120 114 110 102 114 108 106 110 116 122 
13 A 116 118 116 112 116 110 114 118 114 112 
14 A 128 124 128 120 110 108 102 106 110 110 
15 A 116 118 118 118 120 116 114 118 114 116 
16 A 120 118 110 110 112 112 108 119 108 108 
17 A 110 110 120 108 106 100 108 106 110 112 
18 A 108 110 108 120 126 120 118 110 108 110 
19 A 136 130 128 110 106 110 120 126 108 110 
20 A 130 120 118 116 110 108 106 120 126 120 
21 B 110 106 108 110 120 128 120 115 110 110 
22 B 130 126 126 130 126 120 114 115 110 110 
23 B 140 136 140 120 126 128 130 128 126 130 
24 B 110 120 108 120 106 108 116 120 118 120 
25 B 130 140 136 126 126 120 126 120 128 112 
26 B 126 116 106 100 99 98 95 95 100 98 
27 B 130 126 120 108 108 106 120 98 96 98 
28 B 124 126 120 120 112 108 106 116 114 118 
29 B 136 137 132 139 138 130 117 124 119 106 
30 B 126 128 108 106 110 108 116 116 109 109 
31 B 120 124 118 114 118 110 108 108 110 110 
32 B 108 108 110 102 110 108 106 106 116 120 
33 B 120 118 116 120 116 116 114 120 114 110 
34 B 130 138 120 116 110 109 100 106 108 110 
35 B 116 120 120 108 110 116 106 118 110 116 
36 B 130 120 106 110 110 120 110 120 108 108 
37 B 118 110 96 92 90 90 88 92 95 97 
38 B 110 110 106 120 120 120 108 110 108 110 
39 B 126 130 128 120 106 110 108 110 108 110 
40 B 128 110 118 106 110 108 110 120 120 120 
41 C 120 110 110 110 100 100 100 100 100 100 
105 
 
42 C 120 120 120 120 120 110 120 120 130 120 
43 C 120 120 120 120 120 120 120 120 110 110 
44 C 120 120 110 100 100 100 100 100 110 110 
45 C 130 120 120 110 110 110 110 110 100 100 
46 C 140 140 140 130 130 130 130 140 140 150 
47 C 110 110 110 110 110 110 110 110 90 110 
48 C 130 130 130 130 130 130 120 120 110 110 
49 C 120 120 120 110 110 110 110 110 100 100 
50 C 120 120 120 110 110 100 100 100 100 100 
51 C 140 140 130 120 120 130 130 140 140 150 
52 C 130 130 120 120 120 120 120 130 120 120 
53 C 110 110 100 100 100 100 110 110 110 110 
54 C 140 140 130 130 130 120 110 100 110 110 
55 C 110 110 110 100 100 100 100 100 110 110 
56 C 120 120 120 120 120 120 110 110 90 90 
57 C 120 120 120 120 120 120 110 110 90 90 
58 C 120 120 120 120 110 110 100 110 110 110 
59 C 100 110 110 110 110 110 100 100 90 90 
60 C 110 110 110 110 100 100 90 100 100 100 
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S.N
o GROU
P 
INTRA OPERATIVE DIOSTOLIC B.P.(MM HG) 
0 
min 
5 
Min 
10 
min 
15 
min 
30 
min 
45 
min 
60 
min 
90 
min 
120 
min 
150 
min 
1 A 80 70 70 70 70 68 72 74 76 78 
2 A 66 66 66 68 68 68 68 68 70 70 
3 A 70 72 72 68 70 74 70 72 70 72 
4 A 80 72 72 70 72 70 70 70 72 80 
5 A 90 80 80 70 64 70 64 70 70 70 
6 A 80 80 80 70 80 80 80 90 90 80 
7 A 80 80 70 80 70 70 60 60 70 80 
8 A 90 80 80 70 60 60 70 70 70 70 
9 A 70 70 60 60 60 60 60 66 66 66 
10 A 80 70 70 60 70 68 72 74 76 78 
11 A 66 66 66 70 68 68 68 68 70 70 
12 A 70 72 72 68 70 74 70 72 70 72 
13 A 80 70 72 70 72 70 70 70 72 80 
14 A 90 80 80 70 64 70 64 70 70 70 
15 A 80 80 80 70 80 80 80 90 90 80 
16 A 80 80 70 80 70 70 60 60 70 80 
17 A 90 80 80 70 60 60 70 70 70 70 
18 A 70 70 60 60 60 60 60 60 66 66 
19 A 80 80 80 60 70 70 70 70 70 70 
20 A 80 80 80 80 70 60 60 60 60 60 
21 B 80 80 80 70 60 60 60 60 60 60 
22 B 80 80 80 80 80 70 70 66 64 64 
23 B 60 60 60 62 65 70 70 70 70 70 
24 B 80 70 70 70 70 68 72 70 76 78 
25 B 66 66 66 68 68 68 68 60 70 70 
26 B 70 72 72 70 74 74 70 72 72 72 
27 B 80 70 72 70 72 70 70 70 72 80 
28 B 90 80 80 70 64 70 64 70 70 70 
29 B 80 80 80 80 80 80 80 80 90 80 
30 B 80 80 70 70 70 70 60 60 70 80 
31 B 90 80 80 60 60 60 70 90 80 80 
32 B 70 70 60 60 60 60 60 70 70 60 
33 B 80 70 70 70 70 68 72 88 72 58 
34 B 66 66 66 68 68 68 68 80 80 80 
35 B 70 72 72 70 70 74 70 90 89 74 
36 B 80 70 72 70 72 70 70 67 55 64 
37 B 90 80 80 70 64 70 64 87 87 92 
38 B 80 80 80 80 80 80 80 80 70 70 
39 B 80 80 70 70 70 70 60 80 70 70 
40 B 90 80 80 60 60 60 70 80 80 70 
41 C 70 70 72 70 72 70 70 70 72 80 
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42 C 90 80 80 70 64 70 64 70 70 70 
43 C 80 80 70 70 70 70 60 60 70 80 
44 C 90 80 80 60 60 60 70 90 80 80 
45 C 70 70 60 60 60 60 60 70 70 60 
46 C 80 80 70 70 70 70 60 80 70 70 
47 C 68 66 66 68 68 68 68 80 80 80 
48 C 70 72 72 70 70 74 70 90 89 74 
49 C 80 70 72 70 72 70 70 67 55 64 
50 C 90 80 80 70 64 70 64 87 87 92 
51 C 80 80 80 80 80 80 80 80 70 70 
52 C 80 70 70 70 70 68 72 88 72 58 
53 C 90 80 80 60 60 60 70 80 80 70 
54 C 80 80 80 80 80 80 80 80 90 80 
55 C 80 80 80 70 60 50 50 60 60 60 
56 C 80 80 80 80 80 70 70 70 66 60 
57 C 70 70 52 52 62 70 70 70 70 70 
58 C 80 70 70 70 70 68 72 74 76 78 
59 C 66 66 66 68 68 68 68 60 70 70 
60 C 70 72 72 70 70 74 70 72 72 72 
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S.N
o GROU
P 
INTRA OPERATIVE SPO2.(%) 
0 
min 
5 
Min 
10 
min 
15 
min 
30 
min 
45 
min 
60 
min 
90 
min 
120 
min 
150 
min 
1 A 100 99 100 100 100 99 100 100 100 100 
2 A 99 99 100 100 99 100 100 100 100 100 
3 A 100 100 99 99 100 100 100 100 100 100 
4 A 100 100 99 98 99 100 99 100 100 100 
5 A 100 100 99 99 100 100 99 99 100 100 
6 A 100 99 99 100 99 100 100 100 100 100 
7 A 100 100 98 100 98 100 100 99 100 100 
8 A 100 100 99 100 98 100 100 100 100 100 
9 A 100 100 98 100 100 100 100 100 100 100 
10 A 100 100 99 99 99 100 100 100 100 100 
11 A 100 99 98 100 100 100 100 100 100 100 
12 A 100 98 100 99 100 100 100 100 100 100 
13 A 100 99 100 98 99 99 100 100 100 100 
14 A 100 99 100 99 99 100 100 99 100 100 
15 A 100 100 100 100 99 100 100 100 100 100 
16 A 100 99 99 98 100 100 98 100 100 100 
17 A 99 100 98 98 100 100 99 100 100 100 
18 A 100 100 100 99 100 100 99 100 100 100 
19 A 100 98 98 100 100 100 98 99 100 100 
20 A 100 100 99 99 100 99 99 100 100 100 
21 B 99 99 99 99 99 100 100 100 100 100 
22 B 100 100 100 99 99 99 99 99 100 100 
23 B 100 100 100 99 100 100 99 100 100 100 
24 B 100 98 98 100 100 100 98 98 99 99 
25 B 100 99 99 100 99 100 100 100 100 100 
26 B 100 100 98 100 98 100 100 99 100 100 
27 B 100 100 99 100 98 100 100 100 100 100 
28 B 100 99 100 99 99 100 100 99 100 100 
29 B 100 100 100 100 99 100 100 100 100 100 
30 B 100 99 99 98 100 100 98 100 100 100 
31 B 99 100 98 98 100 100 99 100 100 100 
32 B 100 100 99 99 100 99 99 100 100 100 
33 B 100 99 100 100 100 99 100 100 100 100 
34 B 99 99 100 100 99 100 100 100 100 100 
35 B 100 100 99 99 100 100 100 100 100 100 
36 B 100 100 98 100 100 100 100 100 100 100 
37 B 100 100 99 99 99 100 100 100 100 100 
38 B 100 99 98 100 100 100 100 100 100 100 
39 B 100 98 100 99 100 100 100 100 100 100 
40 B 100 99 100 98 99 99 100 100 100 100 
41 C 100 100 100 100 99 100 99 99 99 100 
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42 C 100 99 99 99 100 100 100 100 99 100 
43 C 99 98 98 98 100 100 100 100 99 100 
44 C 100 99 99 99 100 100 100 100 100 100 
45 C 100 100 99 99 100 100 100 100 100 99 
46 C 100 100 98 98 100 100 100 100 100 100 
47 C 99 100 99 99 100 100 99 100 100 100 
48 C 99 100 98 98 99 100 100 100 99 99 
49 C 100 100 100 100 98 99 100 99 99 100 
50 C 100 100 100 100 98 99 99 100 99 100 
51 C 100 100 100 100 99 99 99 100 99 99 
52 C 100 100 100 100 100 100 100 100 100 100 
53 C 100 100 100 100 100 99 100 99 100 100 
54 C 100 100 100 100 100 100 100 100 100 100 
55 C 100 100 100 100 100 99 100 100 100 100 
56 C 100 100 99 100 98 100 99 100 99 100 
57 C 100 99 99 100 97 99 100 100 99 100 
58 C 100 100 99 99 98 100 100 100 100 100 
59 C 100 99 100 100 99 99 100 100 100 100 
60 C 100 100 100 100 100 100 100 100 100 100 
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S.No 
GROUP 
POST OPERATIVE PULSE RATE(BEATS PER MINUTE) 
0 min 15 Min 30 min 1 hr 2 hr 3 hr 4 hr 6 hr 12 hr 24 hr 
1 A 88 88 89 86 89 91 86 88 94 90 
2 A 88 90 90 88 86 82 88 77 77 76 
3 A 88 88 90 90 88 87 90 96 84 89 
4 A 80 80 84 89 85 84 76 84 85 87 
5 A 84 86 87 80 82 76 72 80 86 89 
6 A 80 78 80 85 89 84 90 88 87 87 
7 A 100 104 106 98 95 99 102 98 96 94 
8 A 73 76 75 79 82 87 84 75 76 81 
9 A 86 89 87 90 94 88 83 88 89 81 
10 A 81 87 85 88 90 94 84 79 84 85 
11 A 89 93 97 92 94 88 93 89 88 87 
12 A 88 88 90 90 88 87 90 96 84 89 
13 A 80 80 84 89 85 84 76 84 85 87 
14 A 84 86 87 80 82 76 72 80 86 89 
15 A 82 86 88 96 91 93 84 88 86 89 
16 A 86 86 88 78 73 73 70 74 76 74 
17 A 89 90 90 88 90 86 87 86 88 86 
18 A 86 86 86 82 82 87 87 87 88 86 
19 A 78 82 80 86 88 84 86 84 84 86 
20 A 72 74 74 80 82 78 78 78 82 82 
21 B 102 100 100 99 100 98 96 92 94 92 
22 B 72 68 66 67 67 70 71 70 72 72 
23 B 80 78 80 85 89 84 90 88 87 87 
24 B 100 104 106 98 95 99 102 98 96 94 
25 B 73 76 75 79 82 87 84 75 76 81 
26 B 74 82 80 79 79 80 85 86 85 85 
27 B 75 75 73 70 72 71 76 75 75 75 
28 B 67 75 74 74 75 77 75 75 76 76 
29 B 85 89 91 87 92 95 86 88 87 89 
30 B 90 94 98 99 96 98 104 88 89 94 
31 B 108 110 104 114 116 122 113 102 101 104 
32 B 86 86 88 86 84 88 86 85 71 79 
33 B 96 98 99 100 104 99 92 96 96 92 
34 B 84 86 87 80 82 76 72 80 86 89 
35 B 82 86 88 96 91 93 84 88 86 89 
36 B 74 74 76 78 78 76 76 78 78 82 
37 B 90 90 86 84 84 84 82 82 84 84 
38 B 85 82 86 86 84 85 85 84 83 83 
39 B 80 80 84 89 85 84 76 84 85 87 
40 B 86 86 88 78 73 73 70 74 76 74 
41 C 86 86 88 78 73 73 70 74 76 74 
42 C 89 90 90 88 90 86 87 86 88 86 
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43 C 86 86 86 82 82 87 87 87 88 86 
44 C 78 82 80 86 88 84 86 84 84 86 
45 C 72 74 74 80 82 78 78 78 82 82 
46 C 88 88 89 86 89 91 86 88 94 90 
47 C 88 90 90 88 86 82 88 77 77 76 
48 C 88 88 90 90 88 87 90 96 84 89 
49 C 80 80 84 89 85 84 76 84 85 87 
50 C 86 86 88 78 73 73 70 74 76 74 
51 C 89 90 90 88 90 86 87 86 88 86 
52 C 86 86 86 82 82 87 87 87 88 86 
53 C 78 82 80 86 88 84 86 84 84 86 
54 C 72 74 74 80 82 78 78 78 82 82 
55 C 88 88 90 90 88 87 90 96 84 89 
56 C 80 80 84 89 85 84 76 84 85 87 
57 C 84 86 87 80 82 76 72 80 86 89 
58 C 82 86 88 96 91 93 84 88 86 89 
59 C 74 74 76 78 78 76 76 78 78 82 
60 C 90 90 86 84 84 84 82 82 84 84 
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S.No 
GROUP 
POST OPERATIVE  SYSTOLIC B.P.(MM HG) 
0 min 15 Min 30 min 1 hr 2 hr 3 hr 4 hr 6 hr 12 hr 24 hr 
1 A 100 100 100 100 100 100 100 100 100 100 
2 A 130 120 120 120 120 110 110 110 100 100 
3 A 100 110 110 110 110 110 110 110 110 110 
4 A 100 110 110 110 110 110 110 110 110 110 
5 A 100 100 100 100 100 100 100 100 100 100 
6 A 140 140 150 150 120 120 130 130 130 130 
7 A 90 110 110 110 100 100 100 100 100 100 
8 A 110 110 110 110 120 120 120 120 120 120 
9 A 96 100 100 100 100 100 106 106 106 110 
10 A 100 100 100 100 120 100 100 100 100 100 
11 A 130 120 120 120 100 110 110 110 100 100 
12 A 100 110 110 110 100 110 110 110 110 110 
13 A 100 110 110 110 120 110 110 110 110 110 
14 A 140 100 100 100 110 100 100 100 100 100 
15 A 90 140 150 150 110 120 130 130 130 130 
16 A 110 110 110 110 100 100 100 100 100 100 
17 A 96 110 110 110 120 120 120 120 120 120 
18 A 110 110 100 100 100 100 106 106 106 110 
19 A 100 100 110 110 `120 110 110 110 110 110 
20 A 110 110 96 96 100 100 100 100 106 106 
21 B 110 110 110 120 120 110 110 110 100 109 
22 B 110 108 108 100 110 110 110 110 110 110 
23 B 110 108 108 110 110 110 110 110 110 110 
24 B 100 100 100 100 100 100 100 100 100 100 
25 B 130 120 120 120 120 120 130 130 130 130 
26 B 100 110 110 110 100 100 100 100 100 100 
27 B 100 110 110 110 120 120 120 120 120 120 
28 B 100 100 100 100 100 100 106 106 106 110 
29 B 140 140 150 150 110 110 110 110 110 110 
30 B 90 110 110 110 100 100 100 100 106 106 
31 B 120 120 100 120 120 120 120 110 120 120 
32 B 110 100 120 100 100 100 100 100 100 100 
33 B 110 110 100 110 120 120 120 120 120 120 
34 B 100 100 108 100 100 100 100 110 100 100 
35 B 120 110 100 110 100 100 100 90 100 100 
36 B 110 110 110 110 110 110 110 100 110 110 
37 B 110 110 110 110 110 110 110 120 110 110 
38 B 100 100 110 100 100 100 100 100 100 100 
39 B 120 120 130 130 130 130 130 130 130 130 
40 B 100 100 100 100 100 100 100 110 100 100 
41 C 110 110 110 120 120 110 110 110 105 109 
42 C 110 108 108 100 110 110 110 110 110 110 
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43 C 110 108 108 110 110 110 110 110 110 110 
44 C 100 100 100 100 100 100 100 100 100 100 
45 C 130 120 120 120 120 120 130 130 130 130 
46 C 110 110 110 110 110 110 110 110 100 100 
47 C 100 110 110 110 120 120 120 120 120 120 
48 C 100 100 100 100 100 100 106 106 106 110 
49 C 140 140 150 150 110 110 110 110 110 110 
50 C 90 100 100 100 100 100 100 100 106 106 
51 C 120 120 100 120 120 120 120 110 110 110 
52 C 110 100 120 100 100 100 100 100 100 100 
53 C 110 110 100 110 120 120 120 120 120 120 
54 C 100 100 108 100 100 100 100 110 100 100 
55 C 120 110 100 110 100 100 100 90 100 100 
56 C 110 110 110 110 110 110 110 100 110 110 
57 C 110 110 110 110 110 110 110 120 110 110 
58 C 100 100 110 100 100 100 100 100 100 100 
59 C 120 120 130 130 130 130 130 130 130 130 
60 C 100 100 100 100 100 100 100 110 100 100 
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S.No 
GROUP 
POST OPERATIVE  DIASTOLIC B.P.(MM HG) 
0 min 15 Min 30 min 1 hr 2 hr 3 hr 4 hr 6 hr 12 hr 24 hr 
1 A 70 70 70 70 80 80 80 80 80 80 
2 A 60 66 66 70 70 70 66 66 68 68 
3 A 80 76 78 78 80 80 82 82 82 82 
4 A 70 70 70 70 74 74 74 74 74 74 
5 A 72 70 72 74 74 74 74 74 74 74 
6 A 70 72 80 80 80 80 80 80 80 80 
7 A 70 70 70 70 70 70 70 70 70 70 
8 A 60 60 60 60 60 80 80 80 80 80 
9 A 60 70 80 80 70 70 70 70 70 70 
10 A 70 70 70 70 80 80 80 80 80 80 
11 A 70 70 70 70 60 80 80 80 80 80 
12 A 60 60 60 60 70 60 60 60 70 70 
13 A 60 63 53 70 70 70 70 70 70 70 
14 A 60 80 80 80 80 70 80 70 70 70 
15 A 75 75 71 70 72 70 60 70 75 80 
16 A 70 70 71 85 70 70 70 67 67 70 
17 A 60 49 86 70 70 86 70 70 70 70 
18 A 60 60 72 72 70 70 72 72 72 72 
19 A 60 60 60 60 68 68 68 68 60 60 
20 A 70 72 72 68 68 68 68 70 70 70 
21 B 72 72 80 80 80 80 80 80 82 80 
22 B 70 70 70 72 76 80 80 80 82 80 
23 B 70 70 71 72 70 80 80 80 80 80 
24 B 70 72 71 70 72 68 68 65 67 72 
25 B 55 52 65 75 70 70 70 67 70 70 
26 B 70 49 86 70 70 70 70 70 70 70 
27 B 80 80 80 70 70 70 70 72 74 74 
28 B 60 60 60 70 60 60 60 60 70 70 
29 B 57 63 53 65 70 70 70 70 70 70 
30 B 80 80 80 70 80 70 80 70 70 70 
31 B 72 72 80 80 80 80 80 80 82 80 
32 B 70 70 70 72 70 80 80 80 82 80 
33 B 70 70 71 72 70 80 80 80 75 80 
34 B 75 75 71 70 72 70 68 70 67 80 
35 B 55 52 70 85 70 70 70 67 70 70 
36 B 70 49 86 70 70 70 70 70 70 70 
37 B 80 80 80 70 70 70 70 70 70 70 
38 B 60 60 60 70 60 60 60 60 70 70 
39 B 57 63 53 65 70 70 70 70 70 70 
40 B 80 80 80 70 80 70 80 70 70 70 
41 C 80 80 80 70 70 60 70 80 80 80 
42 C 70 60 60 60 60 60 60 60 60 60 
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43 C 70 70 70 70 70 68 72 70 70 70 
44 C 66 66 66 68 68 68 68 68 66 60 
45 C 70 72 72 70 70 74 70 70 72 70 
46 C 70 70 72 70 72 70 70 70 72 70 
47 C 70 70 80 80 80 70 64 70 70 70 
48 C 80 80 80 80 80 80 80 80 80 80 
49 C 70 70 70 70 70 70 60 70 70 70 
50 C 80 80 80 80 80 60 70 80 80 80 
51 C 80 80 80 80 80 60 70 70 70 70 
52 C 60 60 60 60 60 60 60 70 70 70 
53 C 60 60 58 58 51 76 63 63 63 65 
54 C 80 80 80 80 90 90 90 90 90 90 
55 C 70 70 74 75 70 70 75 75 75 75 
56 C 50 50 64 64 64 59 54 57 57 57 
57 C 87 87 92 83 80 119 86 83 83 80 
58 C 60 60 70 70 60 70 70 80 80 80 
59 C 60 60 70 70 70 60 60 70 70 70 
60 C 60 60 70 60 70 70 70 80 80 80 
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S.No 
GROUP 
sensory 
block 
onset 
motor 
block 
onset 
sensory  
blockduration 
motor 
block 
duration 
duration of 
analgesia Sedationscore 
1 A 10 20 420 500 540 2 
2 A 16 18 560 510 560 2 
3 A 20 22 390 350 420 3 
4 A 16 20 390 420 440 2 
5 A 18 22 540 580 600 3 
6 A 16 18 460 540 610 4 
7 A 18 22 420 360 400 4 
8 A 10 15 300 270 330 3 
9 A 20 22 360 390 410 5 
10 A 22 24 390 370 390 2 
11 A 12 15 450 420 460 3 
12 A 18 20 450 440 480 1 
13 A 16 24 510 360 390 2 
14 A 18 22 420 410 440 3 
15 A 16 22 460 520 540 4 
16 A 15 18 360 400 420 5 
17 A 12 20 510 540 580 3 
18 A 15 18 510 440 560 2 
19 A 20 22 420 380 530 3 
20 A 18 24 330 330 510 3 
21 B 10 15 450 360 460 4 
22 B 12 14 540 510 630 5 
23 B 11 16 540 540 610 6 
24 B 10 15 720 510 560 3 
25 B 15 20 740 710 740 3 
26 B 10 15 700 710 580 2 
27 B 11 13 600 620 590 5 
28 B 12 15 640 700 720 4 
29 B 15 18 620 640 700 6 
30 B 16 20 700 710 650 3 
31 B 10 12 660 690 710 4 
32 B 10 12 620 610 600 2 
33 B 11 16 680 600 640 4 
34 B 10 16 580 420 560 3 
35 B 15 20 560 590 640 3 
36 B 12 15 600 630 720 4 
37 B 12 14 570 560 600 3 
38 B 12 15 700 720 780 5 
39 B 18 22 630 620 640 4 
40 B 16 20 660 640 710 3 
41 C 10 14 760 680 800 4 
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42 C 9 18 760 700 800 4 
43 C 7 10 780 720 800 4 
44 C 8 10 760 740 800 3 
45 C 6 12 680 700 640 6 
46 C 6 15 640 620 620 6 
47 C 9 10 700 700 720 4 
48 C 10 12 690 640 700 5 
49 C 5 10 710 680 720 5 
50 C 8 15 740 760 700 5 
51 C 8 18 740 740 720 4 
52 C 7 10 780 720 820 3 
53 C 5 15 780 700 800 5 
54 C 6 8 800 800 820 5 
55 C 8 12 660 640 680 6 
56 C 8 10 680 710 710 6 
57 C 6 10 770 720 800 3 
58 C 7 12 760 700 780 6 
59 C 8 12 620 700 640 4 
60 C 6 10 640 720 660 5 
 
 
 
 
 
